Adagene, Inc., a platform-driven, clinical-stage biopharmaceutical company, successfully completed its component of the collaboration with Richard Childs, M.D., Chief of the Laboratory of Transplantation Immunotherapy at the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH). Adagene discovered antibodies that Dr. Child’s lab has turned into a CAR-T cell therapy candidate for the potential treatment of renal cell carcinoma, the most common type of kidney c...